Faruqi & Faruqi investigates RxSight securities fraud claims.

Faruqi & Faruqi is investigating potential claims against RxSight for securities fraud. The investigation concerns purchases made between November 7, 2024, and July 8, 2025. Investors who suffered losses are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek the role of lead plaintiff is September 22, 2025.

New York, Aug. 09, 2025 — Faruqi & Faruqi, LLP, a leading national securities law firm, has announced an investigation into potential securities fraud claims against RxSight, Inc. (NASDAQ: RXST). The investigation focuses on purchases made between November 7, 2024, and July 8, 2025. Investors who suffered losses are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights.

The investigation centers on whether RxSight issued misleading statements or failed to disclose information pertinent to investors. On July 8, 2025, after the market closed, RxSight reported significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. The Chief Executive Officer, Ronald Kurtz, disclosed that "adoption challenges over the last few quarters have been a primary reason for the LDD stall."

The stock price of RxSight fell by just under 38% on July 9, 2025, following the announcement. The company's stock closed at $7.95 per share on July 9, 2025, down from $11.89 per share on July 8, 2025.

Investors have until September 22, 2025, to ask the court to be appointed as lead plaintiff in the case. The complaint alleges that RxSight and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the company was experiencing "adoption challenges" and structural issues resulting in declines in sales and utilization. The complaint also alleges that RxSight overstated the demand for its products and failed to disclose that it was unlikely to meet its previously issued financial guidance for fiscal year 2025.

Faruqi & Faruqi encourages anyone with information regarding RxSight's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others. For more information about the RxSight class action, visit www.faruqilaw.com/RXST or call Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

References:
[1] https://www.prnewswire.com/news-releases/rxsight-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--rxst-302521536.html
[2] https://www.morningstar.com/news/pr-newswire/20250805la44361/rxsight-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-rxst
[3] https://www.prnewswire.com/news-releases/faruqi--faruqi-reminds-rxsight-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025---rxst-302525511.html
[4] https://www.globenewswire.com/news-release/2025/08/09/3130452/0/en/RXST-NEWS-Did-RxSight-Inc-Mislead-Investors-Contact-BFA-Law-by-September-22-Class-Action-Deadline-NASDAQ-RXST.html